5-LIPOXYGENASE-ACTIVATING PROTEIN STIMULATES THE UTILIZATION OF ARACHIDONIC-ACID BY 5-LIPOXYGENASE

被引:176
作者
ABRAMOVITZ, M
WONG, E
COX, ME
RICHARDSON, CD
LI, C
VICKERS, PJ
机构
[1] MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,POB 1005,POINTE CLAIRE H9R 4P8,PQ,CANADA
[2] MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,POINTE CLAIRE H9R 4P8,PQ,CANADA
[3] BIOTECHNOL RES INST,VIROL GRP,MONTREAL,PQ,CANADA
[4] MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE H9R 4P8,PQ,CANADA
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1993年 / 215卷 / 01期
关键词
D O I
10.1111/j.1432-1033.1993.tb18012.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
5-Lipoxygenase (5-LO) and its activating protein (FLAP) are both required for cellular leukotriene (LT) synthesis, with 5-LO catalyzing both the synthesis of (5S)-5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HPETE) from arachidonic acid and the subsequent synthesis of LTA4 from 5-HPETE. We have previously expressed both human 5-LO and human FLAP to high levels in Spodoptera frugiperda (Sf9) insect cells, using recombinant baculoviruses. To study the mechanism by which FLAP activates 5-LO, we compared cellular 5-LO activity in Sf9 cells expressing this enzyme to that in Sf9 cells coexpressing FLAP and 5-LO. In this system, FLAP stimulates the utilization of arachidonic acid by 5-LO as a substrate, and increases the efficiency with which 5-LO converts 5-HPETE to LTA4. LT synthesis in cells coexpressing FLAP and 5-LO is inhibited by 3-[l-(p-chlorophenyl)-5-isopropyl-3-tert-butylthio-1H-indol-2-yl]-2,2-dimethyl-propanoic acid (MK-886), an LT biosynthesis inhibitor which specifically binds to FLAP. These studies in Sf9 cells, together with our recent demonstration that FLAP specifically binds arachidonic acid, suggests that FLAP activates 5-LO by acting as an arachidonic acid transfer protein.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 41 条
[1]   PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR [J].
BRIDEAU, C ;
CHAN, C ;
CHARLESON, S ;
DENIS, D ;
EVANS, JF ;
FORDHUTCHINSON, AW ;
FORTIN, R ;
GILLARD, JW ;
GUAY, J ;
GUEVREMONT, D ;
HUTCHINSON, JH ;
JONES, TR ;
LEGER, S ;
MANCINI, JA ;
MCFARLANE, CS ;
PICKETT, C ;
PIECHUTA, H ;
PRASIT, P ;
RIENDEAU, D ;
ROUZER, CA ;
TAGARI, P ;
VICKERS, PJ ;
YOUNG, RN ;
ABRAHAM, WM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) :799-807
[2]  
CHARLESON S, 1992, MOL PHARMACOL, V41, P873
[3]   HUMAN-ENDOTHELIAL CELLS STIMULATE LEUKOTRIENE SYNTHESIS AND CONVERT GRANULOCYTE RELEASED LEUKOTRIENE-A4 INTO LEUKOTRIENE-B4, LEUKOTRIENE-C4, LEUKOTRIENE-D4 AND LEUKOTRIENE-E4 [J].
CLAESSON, HE ;
HAEGGSTROM, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 173 (01) :93-100
[4]   A NOVEL ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PLA2 CONTAINS A CA2+-DEPENDENT TRANSLOCATION DOMAIN WITH HOMOLOGY TO PKC AND GAP [J].
CLARK, JD ;
LIN, LL ;
KRIZ, RW ;
RAMESHA, CS ;
SULTZMAN, LA ;
LIN, AY ;
MILONA, N ;
KNOPF, JL .
CELL, 1991, 65 (06) :1043-1051
[5]  
DENIS D, 1991, J BIOL CHEM, V266, P5072
[6]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284
[7]  
EVANS JF, 1991, MOL PHARMACOL, V40, P22
[8]  
FORDHUTCHINSON AW, 1989, LEUKOTRIENES LIPOXYG, V2, P405
[9]  
FORDHUTCHINSON AW, 1985, LEUKOTRIENES THEIR B, P141
[10]   NATIVE AND MUTANT 5-LIPOXYGENASE EXPRESSION IN A BACULOVIRUS INSECT CELL SYSTEM [J].
FUNK, CD ;
GUNNE, H ;
STEINER, H ;
IZUMI, T ;
SAMUELSSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2592-2596